CEOs must accept the reality that the success of their company is largely dependent on segment dynamics, in addition to the technology or their management skills
Published in Life Science Leader, November 2019
Authors: Dr. Ellen Baron and Dr. Oded Ben-Joseph
Abstract:
Life sciences companies seeking to raise capital or form early partnerships with strategic players often make avoidable mistakes based on misconceptions stem- ming from management’s internal perspective or from overlooking segment dynamics and the importance of return on capital to investors. But there are some tips that can increase your probability of a successful transaction.
Blockbuster drug patent expiration, advances in enabling technology, and the emergence of personalized medicine for prostate cancer treatment create a landscape worth examining.
DownloadOutcome Capital Life Science Market Pulse March 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?